Logo of National Eczema Association mobile menu icon
Icon link to National Eczema's Instagram feed. Icon link to National Eczema's YouTube channel. Icon link to National Eczema's Facebook page. Icon link to National Eczema's Twitter feed. Icon link to National Eczema's inspire.com page. Search Icon to search the site

Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Clinical Trial Details for A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis


Amgen
NCT ID: NCT03809663
Last Updated: August 28, 2019

The Study at a Glance

  • Status: Recruiting
  • Phase: Phase 2
  • Gender: All
  • Age: 18 Years - 75 Years
  • Condition: Atopic Dermatitis
  • Study Type: Interventional
  • Intervention:
  • Lead Sponsor: Amgen
  • Location: Not Provided

Official Title

A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis

Purpose

This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe AD.

Eligibility

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Criteria

Inclusion Criteria:

– Subject has provided informed consent prior to initiation of any study specific
activities/procedures.

– Age greater than or equal to 18 to less than or equal to 75 years at screening.

– Clinical diagnosis of chronic AD (also known as atopic eczema) for at least 2 years
prior to screening and has confirmed AD (Hanifin and Rajka criteria for AD (Hanifin
and Rajka, 1980).

– AD that affects greater than or equal to’ 10% body surface area as assessed by EASI at
screening and on day 1.

– An IGA score of greater than or equal to 3 at screening and on day 1.

– An EASI score of greater than or equal to 16 at screening and on day 1.

– Subject discontinued treatment with TCS, topical calcineurin inhibitors (TCI),
prescription moisturizers, or moisturizers containing additives such as ceramide,
hyaluronic acid, urea, or filaggrin for at least the 7 days immediately prior to the
first dose of investigational product.

– Documented recent history (within 12 months before the screening visit) of inadequate
response totreatment with topical TCS or subjects for whom topical treatments are
otherwise medically inadvisable (ie, because of important side effects or safety
risks).

– Inadequate response is defined as failure to achieve and maintain remission or a low
disease activity state (comparable to IGA 0 = clear to IGA 2 = mild) despite treatment
with a daily regimen of TCS of medium or higher potency (with or without TCI as
appropriate).

Exclusion Criteria:

– Active dermatologic conditions, which might confound the diagnosis of AD or would
interfere with the assessment of treatment, such as scabies, seborrheic dermatitis,
cutaneous lymphoma, ichthyosis, psoriasis, allergic contact dermatitis, or irritant
contact dermatitis.

– History of a clinically significant infection within 28 days prior to day 1 that, in
the opinion of the investigator or medical monitor, might compromise the safety of the
subject in the study, interfere with evaluation of the investigational product, or
reduce the subject’s ability to participate in the study. Clinically significant
infections are defined as either of the following: 1) a systemic infection; or 2) a
serious skin infection requiring parenteral antibiotic, antiviral, or antifungal
medication.

– Diagnosis of a helminth parasitic infection within 6 months prior to screening that
had not been treated with or had failed to respond to standard of care therapy.

– Documented medical history of chronic alcohol or drug abuse within 12 months prior to
screening.

– History of anaphylaxis following any biologic therapy.

– Evidence of active liver disease at screening, including jaundice or aspartate
aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase
greater than twice the upper limit of normal (ULN).

– Diagnosis and/or treatment of tuberculosis within the 12 months prior to screening.

– Positive hepatitis B surface antigen or hepatitis C antibody serology. Subjects with a
history of hepatitis B vaccination without a history of hepatitis B are allowed to
enroll in the study.

– Positive human immunodeficiency virus (HIV) test at screening or the subject is taking
antiretroviral medications, as determined by medical history, prior medications,
and/or the subject’s verbal report.

– Other Medical Conditions>

– History of malignancy, except for basal cell carcinoma or in situ carcinoma of the
cervix treated with apparent success with curative therapy ≥ 12 months prior to
screening or other malignancies treated with apparent success with curative therapy ≥
5 years prior to screening.

– History or evidence of severe depression, schizophrenia, previous suicide attempts, or
suicidal ideation.

Prior/Concomitant Therapy:

– Subjects who are unwilling to abstain from the use of TCS, TCI, prescription
moisturizers, or moisturizers containing additives such as ceramide, hyaluronic acid,
urea, or filaggrin from screening through week 16 (applies only to Part A subjects)

– Subjects who have had side effects of topical medications including intolerance to
treatment, hypersensitivity reactions, significant skin atrophy, or systemic effects
as assessed by the investigator or by the subject’s treating physician (applies only
to Part B subjects)

– More than or equal to 30% of the total lesional surface is located on areas of thin
skin that cannot be safely treated with medium or higher potency TCS (eg, face, neck,
intertriginous areas, areas of skin atrophy) (applies only to Part B subjects)

– Receipt of any approved biologic agent (eg, dupilumab) within 4 months prior to
screening

– Have used immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids,
cyclosporine, mycophenolate-mofetil, interferon (IFN)-gamma, Janus kinase inhibitors,
azathioprine, methotrexate) within 4 weeks prior to screening, or any condition that,
in the opinion of the investigator, is likely to require such treatment(s) during the
first 4 weeks of study treatment.

– Have had phototherapy for AD in the 2 months prior to day 1, and subjects unwilling to
avoid phototherapy during the first 16 weeks of the study

– If on allergen-specific immunotherapy, subjects must be on a maintenance dose and
schedule for ≥ 28 days prior to screening. Allergen-specific immunotherapy is defined
as SC immunotherapy to aeroallergens and/o venom (Hymenoptera) as well as sublingual
immunotherapy to aeroallergens

– Vaccination with a live or attenuated vaccine within 28 days prior to day 1. Receipt
of inactive/killed vaccinations (eg, inactive influenza) is allowed, provided the
vaccinations are not administered within 7 days before or after any study visit. Note
that receipt of the Th2 cytokine inhibitor suplatast within 15 days prior to screening
is allowed.

– Major surgery within 8 weeks prior to screening or planned inpatient surgery or
hospitalization during the study period

– Currently receiving treatment in another investigational device or drug study, or less
than 6 months since ending treatment on another investigational device or drug
study(ies). Other investigational procedures while participating in this study are
excluded.

Other Exclusions:

– Female subject is pregnant or breastfeeding or planning to become pregnant or
breastfeed during treatment and for an additional 14 weeks after the last dose of
investigational product. (Females of childbearing potential should only be enrolled in
the study after a negative highly sensitive serum pregnancy test).

– Female subjects of childbearing potential who are sexually active with unsterilized
male partners unwilling to use 1 highly effective method of contraception during
treatment and for an additional 14 weeks after the last dose of investigational
product. Cessation of contraception after this point must be discussed with a
responsible physician. Females of childbearing potential are defined as those who are
not surgically sterile (ie, had bilateral tubal ligation, bilateral oophorectomy, or
complete hysterectomy) or postmenopausal (defined as 12 months with no menses without
an alternative medical cause). A highly effective method of contraception is defined
as one that resulted in a low failure rate (ie, < 1% per year) when used consistently and correctly. Refer to Appendix 5 for additional contraceptive information.- Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 14 weeks after the last dose of investigational product. Refer to Appendix 5 for additional contraceptive information.- Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 14 weeks after the last dose of investigational product.- Male subjects unwilling to abstain from donating sperm during treatment and for an additional 14 weeks after the last dose of investigational product.- Subject has known sensitivity to any of the products or components to be administered during dosing.- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

Additional Information, Locations & Contacts

Sponsors & Collaborators

Amgen

AstraZeneca

Investigators

Study Director: MD

Amgen

Please refer to this study by its ClinicalTrials.gov identifier: NCT03809663

Location

Contacts

Research Site

Fountain Valley, California 92708

United States

Research Site

Santa Monica, California 90404

United States

Research Site

Alpharetta, Georgia 30022

United States

Research Site

Springfield, Illinois 62702

United States

Research Site

West Dundee, Illinois 60118

United States

Research Site

New Albany, Indiana 47150

United States

Research Site

Overland Park, Kansas 66215

United States

Research Site

Louisville, Kentucky 40217

United States

Research Site

Louisville, Kentucky 40241

United States

Research Site

Clarkston, Michigan 48346

United States

Research Site

Henderson, Nevada 89052

United States

Research Site

New York, New York 10029

United States

Research Site

Stony Brook, New York 11790

United States

Research Site

Nashville, Tennessee 37215

United States

Research Site

Dallas, Texas 75231

United States

Research Site

Spokane, Washington 99202

United States

Research Site

Sydney, New South Wales 2010

Australia

Research Site

Woolloongabba, Queensland 4102

Australia

Research Site

Carlton, Victoria 3053

Australia

Research Site

Parkville, Victoria 3050

Australia

Research Site

Fremantle, Western Australia 6160

Australia

Research Site

Surrey, British Columbia V3R 6A7

Canada

Research Site

London, Ontario N6H 5L5

Canada

Research Site

Markham, Ontario L3P 1X2

Canada

Research Site

Mississauga, Ontario L5A 3V4

Canada

Research Site

Newmarket, Ontario L3Y 5G8

Canada

Research Site

Ottawa, Ontario K1H 7X3

Canada

Research Site

Toronto, Ontario M4V 1R2

Canada

Research Site

Brno, 656 91

Czechia

Research Site

Novy Jicin, 741 01

Czechia

Research Site

Ostrava-Poruba, 708 52

Czechia

Research Site

Praha 1, 110 00

Czechia

Research Site

Praha 8, 180 81

Czechia

Research Site

Tallinn, 13419

Estonia

Research Site

Tartu, 50106

Estonia

Research Site

Tartu, 50417

Estonia

Research Site

Göttingen, 37075

Germany

Research Site

Budapest, 1036

Hungary

Research Site

Debrecen, 4031

Hungary

Research Site

Miskolc, 3529

Hungary

Research Site

Pecs, 7632

Hungary

Research Site

Szeged, 6720

Hungary

Research Site

Sakura-shi, Chiba 285-8741

Japan

Research Site

Fukuoka-shi, Fukuoka 814-0180

Japan

Research Site

Obihiro-shi, Hokkaido 080-0013

Japan

Research Site

Sapporo-shi, Hokkaido 060-0063

Japan

Research Site

Sakai-shi, Osaka 593-8324

Japan

Research Site

Chiyoda-ku, Tokyo 102-8798

Japan

Research Site

Shinagawa-ku, Tokyo 141-8625

Japan

Research Site

Shinjuku-ku, Tokyo 162-8655

Japan

Research Site

Takaoka-shi, Toyama 933-0871

Japan

Research Site

Bucheon-si, Gyeonggi-do, 14584

Korea, Republic of

Research Site

Busan, 49241

Korea, Republic of

Research Site

Seoul, 06973

Korea, Republic of

Research Site

Seoul, 07441

Korea, Republic of

Research Site

Suwon-si, Gyeonggi-do, 16499

Korea, Republic of

Research Site

Riga, 1001

Latvia

Research Site

Riga, 1003

Latvia

Research Site

Riga, 1011

Latvia

Research Site

Ventspils, 3601

Latvia

Research Site

Gdansk, 80-214

Poland

Research Site

Lodz, 90-242

Poland

Research Site

Lodz, 90-436

Poland

Research Site

Lublin, 20-406

Poland

Research Site

Swidnik, 21-040

Poland

Research Site

Warszawa, 01-868

Poland

Research Site

Wroclaw, 50-224

Poland

Research Site

Wroclaw, 51-318

Poland

Research Site

Sevilla, Andalucía 41009

Spain

Research Site

Badalona, Cataluña 08916

Spain

Research Site

Barcelona, Cataluña 08003

Spain

Research Site

Barcelona, Cataluña 08041

Spain

Research Site

Alicante, Comunidad Valenciana 03010

Spain

Research Site

Madrid, 28006

Spain

Research Site

Chernivtsi, 58002

Ukraine

Research Site

Kyiv, 02000

Ukraine

Research Site

Uzhhorod, 88000

Ukraine

Research Site

Zaporizhzhia, 69000

Ukraine

Research Site

Dundee, DD1 9SY

United Kingdom

Research Site

London, E11 1NR

United Kingdom

Research Site

Southampton, SO16 6YD

United Kingdom